Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Bucheon, South Korea Clinical Trials

A listing of Bucheon, South Korea clinical trials actively recruiting patients volunteers.

RESULTS

Found (21) clinical trials

Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj

This is a follow-up study of KD287-BR-CT-301 (ClinicalTrials.gov identifier: NCT01150942), a phase 3 study to investigate the efficacy and safety of a cell-culture Japanese encephalitis vaccine (ENCEVAC®) compared with that of a mouse brain-derived Japanese encephalitis vaccine (Japanese Encephalitis vaccine-GCC® inj). Subjects participated in KD287-BR-CT-301 study were to receive 3 …

Phase

4.66 miles

Learn More »

The Preventive Coronary Intervention on Stenosis With Functionally Insignificant Vulnerable Plaque

Sub-analysis for each imaging test will be performed as below ; NIRS(Near-infrared spectroscopy) OCT(Optical coherence tomography) VH-IVUS(IVUS-derived virtual histology) IVUS(Intravascular ultrasonography)

Phase

4.66 miles

Learn More »

Evaluation of the Efficacy and Safety of Herbal Medicine for Treating Work-related Chronic Low Back Pain

Investigating the efficacy and safety of Sogyeonghwalhyeol-tang(SGHH) on Korean Patients With Work-related Chronic Low Back Pain

Phase

4.66 miles

Learn More »

Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease

To evaluate the safety and therapeutic effectiveness of tolvaptan when administered to slow the progression of cyst development and renal function insufficiency in adult Korean patients diagnosed with rapidly progressive ADPKD who have chronic kidney disease (CKD) stages 1-3 at initiation of treatment.

Phase

4.66 miles

Learn More »

Durvalumab Long-Term Safety and Efficacy Study

This is a multicenter, open-label, global study that will enroll patients who are currently receiving durvalumab monotherapy, or have previously received durvalumab as monotherapy or in combination with any other approved or investigational anticancer agents, in an eligible AstraZeneca/MedImmune-sponsored clinical study.

Phase

4.66 miles

Learn More »

Resolution of Thrombi in Left Atrial Appendage With Edoxaban

Non-valvular (NV) atrial fibrillation (AF) increases the risk of stroke by approximately fivefold. The atrial thrombi associated with AF are seen within the left atrial appendage (LAA) in most cases (> 90%). Anticoagulation with a vitamin-K antagonist (VKA) is recommended to prevent thromboembolic complications and to resolve thrombi. Non-VKA oral …

Phase

4.66 miles

Learn More »

Methylphenidate Treatment Response Study of Genetic Polymorphism in Attention Deficit Hyperactivity Disorder(ADHD)

The purpose of this study is to determine whether norepinephrine gene polymorphism affect to treatment response in ADHD

Phase

4.95 miles

Learn More »

Effects of Combined Therapy With Statin Plus Fenofibrate on Coronary Atherosclerotic Plaque Compared With Statin Alone

Cardiovascular disease remains the leading cause of morbidity and mortality worldwide. In the past few decades, optimal pharmacological therapies with statins targeting LDL-cholesterol substantially reduce the risks of cardiovascular disease. However, the residual cardiovascular risk is still high, requiring need for additional preventive therapies to achieve even greater risk reduction. …

Phase

6.68 miles

Learn More »

S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension

The aim of this study is to verify the difference at week 12 from the baseline value in the average variation of diastolic blood pressure (sitDBP) of the study group in which S-amlodipine / Chlorthalidone combination therapy is to be used in patients with essential hypertension who did not adequately …

Phase

8.35 miles

Learn More »

Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

Patients with partial seizures currently taking 1-3 antiepileptic medications will have a 50:50 chance to receive Lyrica 300 mg per day or placebo (no active ingredients) added on to their current medications for 3 months. Neither the study doctor nor the patient will know the medication assignment. Vision testing will …

Phase

8.35 miles

Learn More »